Recordati Industria Chimica e Farmaceutica SPA (RER1) Stock Price & Analysis
RER1 Stock Chart & Stats
- Day’s Range
- EUR 52.60 - EUR 52.90
- 52-Week Range
- EUR 43.42 - EUR 53.70
- Previous Close
- EUR 52.90
- Volume
- 500
- Average Volume (3M)
- 0
- Market Cap
- EUR 10.94B
- Enterprise Value
- EUR 12.60B
- Total Cash (Recent Filing)
- EUR 391.38M
- Total Debt (Recent Filing)
- EUR 2.31B
- Price to Earnings (P/E)
- 21.8
- Beta
- 0.47
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.50%
Bulls Say, Bears Say
Bulls Say
High Profitability
Gross margins of ~68–73%, EBITDA margins of ~30–37%, and net margins of ~17–19% show a profitable operating model. Sustaining these levels across annual periods and TTM should support reinvestment, resilience, and durable earnings generation over the next several quarters.
Strong Cash Generation
Free cash flow was positive in every reported period and reached about €582M TTM, with roughly 30% TTM growth and ~0.84 conversion versus earnings. This cash backing improves capacity to fund operations and investment while reducing reliance on external financing.
Diversified Pharmaceutical Portfolio
Recordati combines specialty and primary care medicines, including rare-disease treatments, and sells through its own organizations and selected partners across multiple markets. This breadth can support recurring demand and reduce reliance on a single therapeutic area or geography.
Bears Say
Meaningful Leverage
TTM debt-to-equity of ~1.15 indicates leverage remains material despite improvement from ~1.29–1.33 in 2024–2025. This can constrain financial flexibility, increase financing sensitivity, and leave fewer resources available for acquisitions, investment, or shareholder returns.
Cash Flow Variability
Cash generation is positive overall but uneven: 2023 had a notable free cash flow drop, and TTM operating cash flow coverage of ~0.39 was below prior years. Variability and a thinner coverage cushion can make funding less predictable during weaker trading periods.
Margins Below Peak
Although profitability remains strong, peak profitability was in 2021 and margins have been slightly lower since, with EBITDA and net margins below that peak. Continued moderation would reduce incremental earnings from revenue growth and could limit operating leverage.
Recordati Industria Chimica e Farmaceutica SPA News
RER1 FAQ
What was Recordati Industria Chimica e Farmaceutica SPA’s price range in the past 12 months?
What is Recordati Industria Chimica e Farmaceutica SPA’s market cap?
When is Recordati Industria Chimica e Farmaceutica SPA’s upcoming earnings report date?
How were Recordati Industria Chimica e Farmaceutica SPA’s earnings last quarter?
Is Recordati Industria Chimica e Farmaceutica SPA overvalued?
Does Recordati Industria Chimica e Farmaceutica SPA pay dividends?
What is Recordati Industria Chimica e Farmaceutica SPA’s EPS estimate?
How many shares outstanding does Recordati Industria Chimica e Farmaceutica SPA have?
What happened to Recordati Industria Chimica e Farmaceutica SPA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Recordati Industria Chimica e Farmaceutica SPA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops Maapliv for maple syrup urine disease; Isturia for endogenous Cushing’s syndrome; Cystadrops treatment of the ocular manifestations of cystinosis; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fotivda for renal cell carcinoma. It also develops Sylvant for idiopathic multicentric castleman diseases; Caphosol for oral mucositis; ENJAYMO for hemolysis in adults with cold agglutinin disease; Zanidip, Zanipress, Vazkepa, and Logimax for hypertension; Urorec and Avodart for symptoms of benign prostatic hyperplasia; and Livazo for dyslipidemia; Combodart/Duodart; Seloken for angina pectoris, myocardial infarction and cardiac rhythm disorders, as well as hypertension and functional heart disorders. In addition, the company offers Procto-Glyveno for internal and external hemorrhoids; Polydexa, Isofra, and Otofa for ear, nose and throat infections; Isturisa, for Cushing’s syndrome; Normosang, human hemin; Juxtapid, homozygous familial hypercholesterolemia;Ledaga, mycosis fungoides, T-cell cutaneous lymphoma;Tergynan, an anti-infective for gynecological infections; CitraFleet and Phosphosoda as bowel cleansers; Lomexin for gynecological and dermatological infections; Hexaspray, treatments for the oral cavity; Magnesio Supremo, a dietary supplement; Reaglia for schizophrenia; Eligard for hormone-dependent prostate cancer; and pasireotide in Phase II trial for patients with post-bariatric hypoglycemia, as well as other products. The company was founded in 1926 and is headquartered in Milan, Italy.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Robert Koremans
- Employees
- 4,693
- Website
- www.recordati.com
- Address
- Via Matteo Civitali,1, Milan, MI, 20148, IT
Recordati Industria Chimica e Farmaceutica SPA (RER1) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 5 | 1 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 12 | 0 | 0 |